Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

• 收藏
• 分享

专利权人:

Immunomedics; Inc.

发明人:

Govindan, Serengulam V.,Goldenberg, David M.

申请号：

AU2018201403

公开号：

AU2018201403B2

申请日:

2018.02.27

申请国别(地区):

AU

年份:

2019

代理人:

摘要：

#$%^&*AU2018201403B220190718.pdf#####ABSTRACT The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/